CBLLCeriBell, Inc.

1. Aug 10, 2026Ceribell Reports Second Quarter 2026 Financial Results.Earnings release · press release
2. Jul 30, 2026Effective July 28, 2026, the Board of Directors (the “Board”) of CeriBell, Inc. (the “Company”), in order to achieve a more balanced membership among the classes of directors, accepted the resignation of William W. Burke as a Class I director and immediately elected him as a Class II director, and accepted the …Director or officer change · Form 8-K
3. May 11, 2026Ceribell Reports First Quarter 2026 Financial Results.Earnings release · press release
4. Feb 24, 2026Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
5. Jan 5, 2026On January 5, 2026, CeriBell, Inc. (“Ceribell”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) granted Breakthrough Device Designation for Ceribell’s Large Vessel Occlusion (LVO) stroke detection and monitoring solution.Other event · Form 8-K
6. Jan 2, 2026On December 30, 2025, Lucian Iancovici notified the Board of Directors (the “Board”) of CeriBell, Inc. (the “Company”) of his resignation from the Board and from his positions as Chair of the Nominating and Corporate Governance Committee and as a member of the Compensation Committee, effective as of December 31, 2025.Director or officer change · Form 8-K
7. Dec 12, 2025On December 11, 2025, Ceribell, Inc. (the “Company”) and George Yagmourian and Josefa Yagmourian, Trustees of the Yagmourian 1984 Living Trust (the “625 Lessor”), entered into the Second Amendment, effective December 4, 2025 (the “625 Amendment”), to the Standard Industrial/Commercial Multi-Tenant Lease dated May 17 …Material agreement entered · Form 8-K
8. Dec 9, 2025On December 9, 2025, Ceribell, Inc. (“Ceribell”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) granted 510(k) clearance for Ceribell’s proprietary delirium screening and monitoring solution.Other event · Form 8-K
9. Nov 24, 2025On November 24, 2025, Ceribell, Inc. (“Ceribell”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) granted 510(k) clearance for Ceribell’s Clarity Ⓡ algorithm for detecting electrographic seizures in newborns preterm and older.Other event · Form 8-K
10. Nov 4, 2025Ceribell Reports Third Quarter 2025 Financial Results.Earnings release · press release
11. Sep 24, 2025Ceribell, Inc. (the “Company”) and Shenzhen Everwin Precision Technology Co., Ltd. (“Everwin China”) are parties to the Corporate Supply Agreement, dated January 10, 2022, as amended by Amendment No. 1, dated March 7, 2023, and Amendment No. 2, dated November 28, 2023 (collectively, the “Supply Agreement”)Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.